Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Loria

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Science Translational Medicine|June 26, 2015
Developing predictive assays: the phenotypic screening "rule of 3"Fabien Vincent, Paula Loria, Marko Pregel, et al.
Journal of Translational Medicine|October 25, 2011
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonismRena J Eudy, Vaishali Sahasrabudhe, Kevin Sweeney, et al.
Frontiers in Pharmacology|October 18, 2013
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathyStephen Orena, Tristan S Maurer, Li She, et al.
Iscience|April 18, 2024
Type I interferon regulation by USP18 is a key vulnerability in cancerVeronica Jové, Heather Wheeler, Chiachin Wilson Lee, et al.
Scientific Reports|December 2, 2015
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)Kim Huard, Janice Brown, Jessica C Jones, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Science Translational Medicine|June 26, 2015
Developing predictive assays: the phenotypic screening "rule of 3"Fabien Vincent, Paula Loria, Marko Pregel, et al.
Journal of Translational Medicine|October 25, 2011
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonismRena J Eudy, Vaishali Sahasrabudhe, Kevin Sweeney, et al.
Frontiers in Pharmacology|October 18, 2013
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathyStephen Orena, Tristan S Maurer, Li She, et al.
Iscience|April 18, 2024
Type I interferon regulation by USP18 is a key vulnerability in cancerVeronica Jové, Heather Wheeler, Chiachin Wilson Lee, et al.
Scientific Reports|December 2, 2015
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)Kim Huard, Janice Brown, Jessica C Jones, et al.
Pageof 1